Hep C News

FDA Approves New Hepatitis C Treatment Mavyret for All Genotypes

FacebookTwitterLinkedInEmailPrint

The U.S. FDA approved Hepatitis C treatment Mavyret, for all genotypes, for patients without cirrhosis and those with compensated cirrhosis as well as patients with genotype 1 who have been previously treated with an HCV NS5A inhibitor or NS3/4A protease inhibitor but not both and for patients with severe kidney disease, including those on dialysis. …

HealthCare News Newspaper roll with white background
Continue Reading »

FDA Approves Epclusa by Gilead, New Hep C Treatment for All Genotypes

FacebookTwitterLinkedInEmailPrint

June 28, 2016  The US FDA approved the first pan-genotypic (for all genotypes) combination tablet of Epclusa (sofosbuvir/velpatasvir), which is a once-daily fixed dose treatment for Hepatitis C. Epclusa is made by Gilead Sciences who is the current pharma leader with Hepatitis C treatment Harvoni (ledipasvir/sofosbuvir) and Sovaldi (sofosbuvir). Epclusa will bring great benefits to …

epclusabottleandtablet jpg-189656-low
Continue Reading »

FDA Approves Changes to Hep C Treatment Harvoni to expand treatment options

FacebookTwitterLinkedInEmailPrint

FDA approved changes February 12, 2016 to Hep C treatment Harvoni (ledipasvir and sofosbuvir), a fixed dose treatment primary to treat chronic hepatitis C genotype 1, to now include liver transplant patients, genotype 4 liver transplant patients without cirrhosis or with compensated cirrhosis, and genotype 1 patients with decompensated cirrhosis. All major changes also include …

HealthCare News Newspaper roll with white background
Continue Reading »